Benjamin F. Edwards & Company’s Tvardi Therapeutics TVRD Stock Holding History

Benjamin F. Edwards & Company’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$0	Hold	14	–	–	﹤0.01%	2258
2024 Q1	$0	Hold	14	–	–	﹤0.01%	2278
2023 Q4	$0	Hold	14	–	–	﹤0.01%	2190
2023 Q3	$1K	Hold	14	–	–	﹤0.01%	1735
2023 Q2	$1K	Hold	14	–	–	﹤0.01%	1744
2023 Q1	$2K	Hold	14	–	–	﹤0.01%	1706
2022 Q4	$5K	Hold	14	–	–	﹤0.01%	1597
2022 Q3	$5K	Hold	14	–	–	﹤0.01%	1577
2022 Q2	$5K	Hold	14	–	–	﹤0.01%	1559
2022 Q1	$6K	Hold	14	–	–	﹤0.01%	1496
2021 Q4	$6K	Hold	14	–	–	﹤0.01%	1500
2021 Q3	$8K	Buy	14 +6	+75%	+$3.01K	﹤0.01%	1445
2021 Q2	$4K	Hold	8	–	–	﹤0.01%	1566
2021 Q1	$7K	Buy	+8	New	+$5.48K	﹤0.01%	1449

Other funds holding TVRD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Benjamin F. Edwards & Company's TVRD Position: Q2 2024 in Review

Benjamin F. Edwards & Company held its Tvardi Therapeutics (TVRD) position steady in Q2 2024 at 14 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2258.

Benjamin F. Edwards & Company first reported a position in TVRD in Q1 2021 and has held it in 14 quarters since. The position peaked at $8K in Q3 2021. 79 funds tracked by Wall St. Rank hold TVRD as of Q2 2024.

Benjamin F. Edwards & Company held 14 shares of Tvardi Therapeutics worth $0 as of Q2 2024.
Benjamin F. Edwards & Company left its Tvardi Therapeutics share count unchanged in Q2 2024.
Tvardi Therapeutics made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #2258 holding.
Benjamin F. Edwards & Company first reported a position in Tvardi Therapeutics in Q1 2021 and has held it in 14 quarters since.
Benjamin F. Edwards & Company's Tvardi Therapeutics position peaked at $8K in Q3 2021.
79 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.